- Home
- WETH vs NLSP Comparison
WETH vs NLSP Comparison
Compare WETH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETH
- NLSP
- Stock Information
- Founded
- WETH 1992
- NLSP 2015
- Country
- WETH China
- NLSP Switzerland
- Employees
- WETH N/A
- NLSP N/A
- Industry
- WETH
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- WETH
- NLSP Health Care
- Exchange
- WETH Nasdaq
- NLSP Nasdaq
- Market Cap
- WETH 10.9M
- NLSP 12.4M
- IPO Year
- WETH N/A
- NLSP 2021
- Fundamental
- Price
- WETH $1.49
- NLSP $1.87
- Analyst Decision
- WETH
- NLSP
- Analyst Count
- WETH 0
- NLSP 0
- Target Price
- WETH N/A
- NLSP N/A
- AVG Volume (30 Days)
- WETH 245.1K
- NLSP 943.2K
- Earning Date
- WETH 11-13-2025
- NLSP 10-06-2025
- Dividend Yield
- WETH N/A
- NLSP N/A
- EPS Growth
- WETH N/A
- NLSP N/A
- EPS
- WETH 0.71
- NLSP N/A
- Revenue
- WETH $42,692,692.00
- NLSP N/A
- Revenue This Year
- WETH N/A
- NLSP N/A
- Revenue Next Year
- WETH N/A
- NLSP N/A
- P/E Ratio
- WETH $1.96
- NLSP N/A
- Revenue Growth
- WETH 6.48
- NLSP N/A
- 52 Week Low
- WETH $0.76
- NLSP $1.30
- 52 Week High
- WETH $2.85
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- WETH 70.23
- NLSP 42.28
- Support Level
- WETH $1.16
- NLSP $1.81
- Resistance Level
- WETH $1.77
- NLSP $2.15
- Average True Range (ATR)
- WETH 0.15
- NLSP 0.19
- MACD
- WETH 0.00
- NLSP -0.02
- Stochastic Oscillator
- WETH 48.30
- NLSP 13.57
About WETH Wetouch Technology Inc.
Wetouch Technology Inc is a touch panel supplier focused on R & D, production and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots and charging stations. The company sells touchscreen products both domestically in China and internationally, covering the majority of areas in China, Taiwan, South Korea, and Germany.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.